Bio-AMD Inc.

CIK:0001370030|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Expenses:
General and administrative charges (Note 4)	$ 68,099	$ 160,781	$ 325,693	$ 739,277
Total operating expense	68,099	160,781	325,693	739,277
Net loss before other income	(68,099)	(160,781)	(325,693)	(739,277)
Other income:
Gain on termination of research agreement (Note 5)	0	0	248,074	0
Grant income	0	77,872	0	77,872
Interest and other income	439	668	1,401	2,192
Net income (loss)	(67,660)	(82,241)	(76,218)	(659,213)
Net loss (income) attributable to the non-controlling interest	22,815	(16,682)	(21,095)	(9,382)
Net loss attributable to Bio-AMD, Inc. common shareholders	(44,845)	(98,923)	(97,313)	(668,595)
Comprehensive Loss:
Net income (loss)	(67,660)	(82,241)	(76,218)	(659,213)
Foreign currency translation adjustment, net of tax	(16,867)	26,402	(33,921)	(14,400)
Total other comprehensive income (loss)	(84,527)	(55,839)	(110,139)	(673,613)
Comprehensive (income)/loss attributable to the non-controlling interest	19,861	19,990	(44,668)	(13,702)
Comprehensive loss attributable to the Bio-AMD Inc. Common Shareholders	$ (64,666)	$ (35,849)	$ (154,807)	$ (687,315)
Net loss per common share attributable to Bio-AMD, Inc. common shareholders - basic and diluted (in Dollars per share)	$ 0.00	$ 0.00	$ 0.00	$ (0.01)
Weighted average number of common shares outstanding - basic and diluted (in Shares)	45,975,966	45,975,966	45,975,966	45,266,425

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (76,218)	$ (659,213)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of prepaid stock based fees	0	39,000
Gain on termination of research agreement	(248,074)	0
Stock based consulting fees	0	184,000
Changes in operating assets and liabilities:
Prepaid expenses	2,821	(11,456)
Amounts receivable	5,393	10,523
Deferred charges	(46,879)	(534,295)
Security deposit and other assets	0	(24,443)
Accounts payable and accrued expenses	(8,700)	67,689
Other liabilities	(16,568)	9,717
Deferred revenue	0	983,790
Total Adjustments	(312,007)	724,525
Net cash used in operating activities	(388,225)	65,312
Cash flows used in investing activities:
Patent expenditures	(34,890)	0
Net cash used in investing activities	(34,890)	0
Cash flows from financing activities:
Proceeds from investment in MIDS Medical	130,000	0
Net cash provided by financing activities	130,000	0
Effects of exchange rate changes on cash	(21,333)	(16,948)
Net (decrease) increase in cash	(314,448)	48,364
Cash, beginning of period	437,400	717,144
Cash, end of period	122,952	765,508
Cash paid during the period for:
Interest	0	0
Income tax	0	0
Common stock issued for prepaid services	$ 0	$ 54,000

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current Assets:
Cash	$ 122,952	$ 437,400
Amounts receivable	7,579	12,972
Prepaid expenses	9,430	12,251
Deferred charges	0	645,534
Total Current Assets	139,961	1,108,157
Property and equipment, net	138	157
Patents (Note 3)	178,254	165,848
Total Assets	318,353	1,274,162
Current Liabilities:
Accounts payable	59,414	62,149
Accrued liabilities	17,274	23,239
Other liabilities	748	17,316
Deferred revenue		950,402
Total Liabilities	77,436	1,053,106
Nature of Operations and Continuation of Business (note 1)
Commitment (Note 7)
Stockholders' Equity:
Preferred stock, 10,000,000 shares authorized, $0.001 par value, nil shares issued and outstanding	0	0
Common stock, 500,000,000 shares authorized, $0.001 par value, 45,975,966 shares issued and outstanding	45,976	45,976
Additional Paid-in Capital	42,741,186	42,589,759
Accumulated other comprehensive income	15,749	73,243
Accumulated deficit	(41,429,171)	(41,331,858)
Total Bio-AMD, Inc. Stockholders' Equity	1,373,740	1,377,120
Non-controlling interest	(1,132,823)	(1,156,064)
Total Stockholders' Equity	240,917	221,056
Total Liabilities and Stockholders' Equity	$ 318,353	$ 1,274,162